5 November 2026
Latham & Watkins Advises AbbVie on Global License Agreement With Nxera Pharma
Advising firms
Deal team
8 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Aaron Gardner Lead | Latham & Watkins LLP | Partner | Life Sciences Licensing | New York |
| Robert Yeh | Latham & Watkins LLP | Counsel | Life Sciences Licensing | San Diego |
| Patrick Chew | Latham & Watkins LLP | Associate | Life Sciences Licensing | Not stated |
| Ian Conner | Latham & Watkins LLP | Partner | antitrust | Washington, D.C. |
| Héctor Armengod | Latham & Watkins LLP | Partner | antitrust | Brussels |
| Gregory Bonné | Latham & Watkins LLP | Partner | antitrust | London |
| Oscar Hayward | Latham & Watkins LLP | Associate | antitrust | Not stated |
| Bernie Archbold | Latham & Watkins LLP | Associate | antitrust | Not stated |
5 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 100m (US$100 million)
- What the figure measures
- Total transaction value
- Client
- AbbVie Inc.Buy-side
- Counterparties
- Nxera Pharma Co., Ltd. (Sell-side)